Novo Nordisk (NVO) Capital Markets Day preview
Disappointing CagriSema trial data have put Novo Nordisk (CPH: NOVOB) (NYSE: NVO) shares under pressure. But UBS’ preview into the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)